Title : Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis - Jann_2004_Pharmacotherapy_24_1759 |
Author(s) : Jann MW |
Ref : Pharmacotherapy , 24 :1759 , 2004 |
Abstract : |
PubMedSearch : Jann_2004_Pharmacotherapy_24_1759 |
PubMedID: 15585443 |
Title : Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors - Jann_2002_Clin.Pharmacokinet_41_719 |
Author(s) : Jann MW , Shirley KL , Small GW |
Ref : Clinical Pharmacokinetics , 41 :719 , 2002 |
Abstract : |
PubMedSearch : Jann_2002_Clin.Pharmacokinet_41_719 |
PubMedID: 12162759 |
Title : Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly - VanDenBerg_2000_Drugs.Aging_16_123 |
Author(s) : VanDenBerg CM , Kazmi Y , Jann MW |
Ref : Drugs & Aging , 16 :123 , 2000 |
Abstract : |
PubMedSearch : VanDenBerg_2000_Drugs.Aging_16_123 |
PubMedID: 10755328 |
Title : Supportive care for the patient with Alzheimer's disease - Jann_2000_J.Am.Pharm.Assoc.(Wash)_40_S50 |
Author(s) : Jann MW , Brandt N |
Ref : J Am Pharm Assoc (Wash) , 40 :S50 , 2000 |
Abstract : |
PubMedSearch : Jann_2000_J.Am.Pharm.Assoc.(Wash)_40_S50 |
PubMedID: 11029868 |
Title : Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease - Jann_2000_Pharmacotherapy_20_1 |
Author(s) : Jann MW |
Ref : Pharmacotherapy , 20 :1 , 2000 |
Abstract : |
PubMedSearch : Jann_2000_Pharmacotherapy_20_1 |
PubMedID: 10641971 |
Title : Pharmacology and clinical efficacy of cholinesterase inhibitors - Jann_1998_Am.J.Health.Syst.Pharm_55 Suppl 2_S22 |
Author(s) : Jann MW |
Ref : Am J Health Syst Pharm , 55 Suppl 2 :S22 , 1998 |
Abstract : |
PubMedSearch : Jann_1998_Am.J.Health.Syst.Pharm_55 Suppl 2_S22 |
PubMedID: 9809108 |
Title : Preclinical pharmacology of metrifonate - Jann_1998_Pharmacotherapy_18_55 |
Author(s) : Jann MW |
Ref : Pharmacotherapy , 18 :55 , 1998 |
Abstract : |
PubMedSearch : Jann_1998_Pharmacotherapy_18_55 |
PubMedID: 9543466 |